CLLSCellectis S.A. American Depositary Shares

ADRCNasdaq (XNAS)·USD

Identity

Security key: 13476
Ticker: CLLS
Type: ADRC — American Depository Receipt Common
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2015-03-25
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: CLLS

Detail

Enriched 2026-08-14 20:47

Market cap: $296,052,584.52
Shares outstanding (class): 72,093,635
Shares outstanding (weighted): 100,698,158
SIC: —
Employees: 229
Location: —
Homepage: https://www.cellectis.com
Description: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Market cap and share counts drift.

Funds holding this security

2 funds · 2 positions · $1.80M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Biotechnology ETF iShares Trust	IBB	$1.08M	0.01%	339,873 NS	FIGI
Nomura Healthcare Fund Delaware Group Equity Funds IV	—	$719.2K	0.11%	226,875 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERCLLS
FIGI_COMPOSITEBBG0084L1XN2
FIGI_SHARE_CLASSBBG0084L1YD1
CIK0001627281
ISINUS15117K1034
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Cellectis is a clinical-stage biotech company developing gene-edited CAR T-cell immunotherapies.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.